Abstract
Purpose
To elucidate the role of D-type cyclins in both superficial (Ta–T1) and muscle-invasive (T2–T4) urothelial carcinomas (UCs), investigating their potential prognostic usefulness.
Methods
Paraffin-embedded tissues from 157 patients with bladder UC were immunostained for cyclins D1, D2 and D3.
Results
Cyclin D1 expression positively correlated with D2 and negatively with D3. Cyclin D1 expression decreased with increasing grade (P = 0.0001) and tumour T-category in the entire cohort and in muscle-invasive carcinomas (P = 0.0001 and P = 0.0033). Cyclin D2 correlated with grade (P = 0.0005) and T-category (P = 0.0078), a relationship which remained significant in muscle-invasive (P = 0.0135). Cyclin D3 immunoreactivity increased with histologic grade and T-category in the entire cohort (P = 0.0001 in both relationships), in superficial (P = 0.0034) and in muscle-invasive carcinomas (P = 0.0036, respectively). Survival analysis in superficial tumours showed that higher cyclin D1 (P = 0.0001) and higher cyclin D3 levels (P = 0.0032) were correlated with a lesser probability of survival. In muscle-invasive tumours, lower cyclin D1 (P = 0.0234), and D2 (P = 0.0424) and higher cyclin D3 (P = 0.0322) correlated with shortened survival. In multivariate analysis in superficial tumours only cyclin D3 expression remained significant. Cyclin D3 expression also retained its adverse significance in muscle-invasive tumours.
Conclusions
Cyclin D1 overexpression seems to be more important during early T-categories of bladder carcinogenesis, whereas cyclin D3 is implicated in the acquisition of a more aggressive phenotype. Cyclin D3 overexpression emerges as an independent adverse prognostic marker in both superficial and muscle-invasive tumours. Cyclin D1 is an independent indicator of shortened survival only in muscle-invasive tumours.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bali A, O’Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM (2004) Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10:5168–5177
Bartkova J, Lukas J, Strauss M, Bartek J (1998) Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 17:1027–1037
Bribguer PP, Tamimi Y, Schuuring E, Schalken J (1996) Expression of cyclin D1 and EmS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene 12:1747–1753
Buchkovich K, Duffy LA, Harlow E (1989) The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58(6):1097–1105
Büschges R, Weber RG, Actor B, Lichter P, Collins VP, Reifenberger G (1999) Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 9(3):435–442
Eble JN, Epstein JI, Seternhenn IA (2004) World Health Organization classification of tumours. Pathology and genetics, tumours of the urinary system and male genital track. IARC Press, Lyon, pp 89–115
Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, Skrabs C, Pirker R (2002) Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 8(3):729–733
Gao P, Zhou GY, Liu Y, Li JS, Zhen JH, Yuan YP (2004) Alteration of cyclin D1 in gastric carcinoma and its clinicopathologic significance. World J Gastroenterol 10(20):2936–2939
Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D (1996) Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92–99
Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH, Harris CC, Motnesano R, Weinstein IB (1993) Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Sci USA 90:9026–9030
Korkolopoulou P, Konstantinidou AE, Thomas-Tsagli E, Christodoulou P, Kapralos P, Davaris P (2000) WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer. Appl Immunohistochem Mol Morphol 8(4):285–292
Lee CC, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, Ikemoto S, Nakatani T, Wada S, Kishimoto T, Fukushima S (1997) Significance of Cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 79:780–789
Levidou G, Korkolopoulou P, Thymara I, Vassilopoulos I, Saetta AA, Gakiopoulou H, Konstantinidou A, Kairi-Vassilatou E, Pavlakis K, Patsouris E (2007) Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas. Int J Gynecol Pathol 26(4):410–417
Levidou G, Saetta AA, Korkolopoulou P, Papanastasiou P, Gioti K, Pavlopoulos P, Diamantopoulou K, Thomas-Tsagli E, Xiromeritis K, Patsouris E (2008) Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder. Virchows Arch 452(3):295–304
Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco JC, Requena MJ, Montironi R (2004a) Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 45(5):606–612
Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, Montironi R (2004b) Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 122(3):444–452
Lopez-Beltran A, Requena MJ, Luque RJ, Alvarez-Kindelan J, Quintero A, Blanca AM, Rodriguez ME, Siendones E, Montironi R (2006) Cyclin D3 expression in primary Ta/T1 bladder cancer. J Pathol 209(1):106–113
Mikulowski P, Hellsten S (2004) T1G1 urinary bladder carcinoma: fact or fiction? Scand J Urol Neph 39:135–137
Pagano M, Theodoras AM, Tam SW, Draetta GF (1994) Cyclin D1- mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 8:1627–1639
Peng SY, Chou SP, Hsu HC (1998) Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepat 29:281–289
Proctor AJ, Coombs JM, Cairns JP, Knowles MA (1991) Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene 6:789–795
Pryor JP (1973) Factors influencing the survival of patients with transitional cell tumours of the urinary bladder. Br J Urol 45:586–591
Rosenberg CL, Kim HG, Shows TB, Kronenberg HM, Arnold A (1991) Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene 6(3):449–453
Sherr CJ (2000–2001) Cell cycle control and cancer. Harvey Lect 96:73–92
Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I (1999) Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol 189(2):194–200
Vermeulen K, Berneman ZN, Van Bockstaele DR (2003) Cell cycle and apoptosis. Cell Prolif 36(3):165–175
Conflict of Interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Levidou, G., Saetta, A.A., Karlou, M. et al. D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. J Cancer Res Clin Oncol 136, 1563–1571 (2010). https://doi.org/10.1007/s00432-010-0814-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-010-0814-y